Compare LION & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | MIRM |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 3.4B |
| IPO Year | N/A | 2019 |
| Metric | LION | MIRM |
|---|---|---|
| Price | $8.99 | $80.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $9.11 | ★ $92.45 |
| AVG Volume (30 Days) | ★ 2.5M | 802.1K |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,858,000,000.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $22.30 | $19.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 21.18 | ★ 53.66 |
| 52 Week Low | $5.55 | $36.88 |
| 52 Week High | $9.24 | $81.70 |
| Indicator | LION | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 76.68 | 67.61 |
| Support Level | $8.21 | $63.23 |
| Resistance Level | $8.75 | $66.77 |
| Average True Range (ATR) | 0.42 | 3.70 |
| MACD | 0.08 | 1.62 |
| Stochastic Oscillator | 89.41 | 84.91 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.